AnaptysBio, a clinical-stage biotechnology company based in San Diego, focuses on immune cell modulators and has two checkpoint agonists in Phase 2 trials for autoimmune diseases. The company went public on January 26, 2017, and employs 117 staff.
Dennis Mulroy sold 12,220 shares of ANAB on 16 September at $40.13 per share, worth a total of $490K. They now own 4,744 ANAB shares, or a 72% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
